Hebei Super Pharmaceutical is currently composed of two companies, Hebei Super Rise Pharmaceutical Technology Co., Ltd. and Hebei Super Sunshine Pharmaceutical Technology Co., Ltd. Hebei Super Rise Pharmaceutical Technology Co., Ltd. was established in July 2019 and is located in Shijiazhuang High-tech Industrial Development Zone, Hebei Province. It is a pharmaceutical technology research and development company mainly engaged in new drug research and development, generic drug consistency evaluation, and special medical food development. The company is committed to innovative drug development, and the company's outstanding highlight is that its products are compatible with industrialization. The company was formerly known as the Drug Research Institute of Zhitong Pharmaceutical Holding Group. Hebei Super Sunshine Pharmaceutical Technology Co., Ltd. was established on June 23, 2020. The company has established a complete MAH drug certification quality management system, and has quality management, risk prevention and control systems and liability compensation capabilities to ensure the safety, effectiveness and quality controllability of drugs. It obtained a drug production license on August 12, 2024.

Product classification

Hebei Super Sunshine Pharmaceutical

Committed to innovative drug development and product alignment with industrialization

It obtained a drug production license on August 12, 2024.

News Centermore

  • 08/04/2025 15:09:02

    The National Medical Products Administration: The 2025 Edition of the Chinese Pharmacopoeia is officially promulgated.

    In accordance with the "Pharmaceutical Administration Law of the People's Republic of China", the 2025 Edition of the "Pharmacopoeia of the People's Republic of China" (hereinafter referred to as the "Chinese Pharmacopoeia") has been reviewed and approved by the plenary session of the 12th Pharmacopoeia Committee Executive Committee. It is hereby promulgated and shall come into effect on October 1, 2025. The table of contents of the 2025 Edition of the "Chinese Pharmacopoeia" is attached.
    This is to announce.
    Attachment 1: Catalogue of the First Part of the 2025 Edition of the Chinese Pharmacopoeia
    Attachment 2: Catalogue of the Second Part of the 2025 Edition of the Chinese Pharmacopoeia
    Attachment 3: Catalogue of the Third Part of the 2025 Edition of the Chinese Pharmacopoeia
    Attachment 4: Catalogue of the Fourth Part of the 2025 Edition of the Chinese Pharmacopoeia
    National Medical Products Administration
    National Health Commission
    March 20, 2025

Antioxidant BHT 264

CAS:128-37-0

Purity:99%

Contact Now

We will contact you as soon as possible


提交